Safety and long‐term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension

Authors:

Abstract
Nebulization delivery of adeno‐associated virus serotype 1 encoding sarcoplasmic reticulum Ca2+‐ATPase2a (AAV1.SERCA2a) gene was examined in a Yukatan miniature swine model of chronic pulmonary hypertension (n = 13). Nebulization of AAV1.SERCA2a resulted in homogenous distribution of vectors, lower pulmonary vascular resistance, and a trend towards better long‐term survival compared to control animals.
Funding Information
  • National Institutes of Health (R01 HL117505, HL 119046, HL129814, HL128072, HL131404, HL135093, HL112324, HL139963)
  • Deutsche Herzstiftung
  • Fondation Leducq
  • American Heart Association (17SDG33410873)
  • National Heart, Lung, and Blood Institute (Gene Therapy Resource Program)
  • National Heart, Lung, and Blood Institute (HL112324)
  • National Heart, Lung, and Blood Institute (HL117505)
  • National Heart, Lung, and Blood Institute (HL119046)
  • National Heart, Lung, and Blood Institute (HL128072)
  • National Heart, Lung, and Blood Institute (HL129814)
  • National Heart, Lung, and Blood Institute (HL131404)
  • National Heart, Lung, and Blood Institute (HL135093)
  • National Heart, Lung, and Blood Institute (HL139963)